ATE295178T1 - Azellulärer pertussis-impfstoff, der ein diphtheriae- und tetanus-toxoid enthält - Google Patents

Azellulärer pertussis-impfstoff, der ein diphtheriae- und tetanus-toxoid enthält

Info

Publication number
ATE295178T1
ATE295178T1 AT02075821T AT02075821T ATE295178T1 AT E295178 T1 ATE295178 T1 AT E295178T1 AT 02075821 T AT02075821 T AT 02075821T AT 02075821 T AT02075821 T AT 02075821T AT E295178 T1 ATE295178 T1 AT E295178T1
Authority
AT
Austria
Prior art keywords
acecellular
diphtheriae
tetanus toxoid
vaccine containing
pertussis vaccine
Prior art date
Application number
AT02075821T
Other languages
English (en)
Inventor
Patrick Florent
Jean Stephenne
Christian Vandecasserie
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of ATE295178T1 publication Critical patent/ATE295178T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0016Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/05Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/099Bordetella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K2039/10Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT02075821T 1996-11-07 1997-11-04 Azellulärer pertussis-impfstoff, der ein diphtheriae- und tetanus-toxoid enthält ATE295178T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9623233.5A GB9623233D0 (en) 1996-11-07 1996-11-07 Vaccine composition

Publications (1)

Publication Number Publication Date
ATE295178T1 true ATE295178T1 (de) 2005-05-15

Family

ID=10802615

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02075821T ATE295178T1 (de) 1996-11-07 1997-11-04 Azellulärer pertussis-impfstoff, der ein diphtheriae- und tetanus-toxoid enthält
AT97950137T ATE222773T1 (de) 1996-11-07 1997-11-04 Azellulärer pertussis-impfstoff, der ein diphtherie-toxoid und ein tetanus-toxoid enthält

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97950137T ATE222773T1 (de) 1996-11-07 1997-11-04 Azellulärer pertussis-impfstoff, der ein diphtherie-toxoid und ein tetanus-toxoid enthält

Country Status (30)

Country Link
EP (2) EP1240905B3 (de)
JP (1) JP3980652B2 (de)
KR (1) KR100518044B1 (de)
CN (1) CN1130226C (de)
AR (1) AR011509A1 (de)
AT (2) ATE295178T1 (de)
AU (1) AU710475B2 (de)
BR (2) BRPI9712917B8 (de)
CA (1) CA2271008C (de)
CO (1) CO4910171A1 (de)
CY (2) CY2407B1 (de)
CZ (1) CZ295954B6 (de)
DE (3) DE69733285T3 (de)
DK (2) DK0941117T3 (de)
ES (2) ES2240647T7 (de)
GB (1) GB9623233D0 (de)
HK (1) HK1050473B (de)
HU (1) HU224126B1 (de)
IL (1) IL129530A (de)
LU (1) LU91183I2 (de)
NO (2) NO320186B1 (de)
NZ (1) NZ335384A (de)
PL (1) PL188460B1 (de)
PT (2) PT1240905E (de)
SA (1) SA98181128B1 (de)
SI (2) SI1240905T1 (de)
TR (1) TR199900979T2 (de)
TW (1) TW471971B (de)
WO (1) WO1998019702A1 (de)
ZA (1) ZA979984B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004314A1 (de) * 1998-11-26 2000-05-31 Pasteur Merieux MSD T.d.Polio Impstoff für einer primovakzinierter oder empfindlicher Population
KR100374813B1 (ko) * 2000-04-07 2003-03-03 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드, 정제백일해 및비형간염표면항원을 포함한 4가 혼합백신 및 그 제조 방법
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
JP5007425B2 (ja) * 2006-01-30 2012-08-22 財団法人ヒューマンサイエンス振興財団 百日咳ワクチンの安全性評価方法
GB0616306D0 (en) * 2006-08-16 2006-09-27 Novartis Ag Vaccines
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
AU2011295853A1 (en) 2010-09-01 2013-04-04 Irm Llc Adsorption of immunopotentiators to insoluble metal salts
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
CN102363041A (zh) * 2011-11-17 2012-02-29 成都欧林生物科技股份有限公司 不含防腐剂疫苗的制作工艺
MX372965B (es) * 2012-03-08 2020-04-01 Glaxosmithkline Biologicals Sa Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
CN102793915B (zh) * 2012-07-25 2013-10-23 天津康希诺生物技术有限公司 一种无细胞百日咳疫苗的生产方法
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
CN103100081A (zh) * 2012-12-26 2013-05-15 天津康希诺生物技术有限公司 一种多价联合疫苗
WO2014135651A1 (en) 2013-03-08 2014-09-12 Crucell Holland B.V. Acellular pertussis vaccine
MX2016001695A (es) 2013-08-05 2016-05-02 Glaxosmithkline Biolog Sa Composiciones inmunogenas de combinacion.
CN114748616A (zh) * 2022-05-23 2022-07-15 中国医学科学院医学生物学研究所 一种成人青少年用无细胞百白破联合疫苗及其制备方法
CN117417419B (zh) * 2023-01-10 2024-04-19 康希诺生物股份公司 一种百日咳毒素脱毒方法及无细胞百白破联合疫苗
CN119524117B (zh) * 2025-01-23 2025-09-23 康希诺生物股份公司 免疫原性组合物、百白破联合疫苗及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
AP56A (en) 1987-01-30 1989-09-26 Smithkline Biologicals S A Hepatitis B virus surface antigens and hybrid antigehs containing them.
EP1088830A3 (de) 1987-06-22 2004-04-07 Medeva Holdings B.V. Partikel von Hepatitis B Oberflächenantigen
DE3789866T2 (de) 1987-07-17 1994-09-22 Rhein Biotech Gesellschaft Fuer Neue Biotechnologische Prozesse Und Produkte Mbh, 40595 Duesseldorf DNA-Moleküle, die für FMDH-Kontrollabschnitte und Strukturgene für ein Protein mit FMDH-Aktivität kodieren, sowie deren Anwendung.
EP0414374B1 (de) 1989-07-25 1997-10-08 Smithkline Biologicals S.A. Antigene sowie Verfahren zu deren Herstellung
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
SG48365A1 (en) * 1992-05-23 1998-04-17 Smithkline Beecham Biolog Combined vaccines comprising hepatitis b surface antigen and other antigens

Also Published As

Publication number Publication date
EP0941117A1 (de) 1999-09-15
AR011509A1 (es) 2000-08-30
CN1130226C (zh) 2003-12-10
CO4910171A1 (es) 2000-04-24
DK1240905T5 (da) 2010-01-11
DK0941117T3 (da) 2002-11-18
ES2240647T3 (es) 2005-10-16
HUP9904287A3 (en) 2001-05-28
DE69733285T3 (de) 2010-03-25
KR20000053092A (ko) 2000-08-25
KR100518044B1 (ko) 2005-09-30
NO992156L (no) 1999-05-04
JP2001503422A (ja) 2001-03-13
NZ335384A (en) 2000-10-27
NO2006005I1 (no) 2006-05-08
CN1236321A (zh) 1999-11-24
HUP9904287A1 (hu) 2000-04-28
BRPI9712917B1 (pt) 2019-12-03
PT1240905E (pt) 2005-09-30
CY2568B1 (en) 2008-07-02
WO1998019702A1 (en) 1998-05-14
PL188460B1 (pl) 2005-02-28
CA2271008A1 (en) 1998-05-14
CZ295954B6 (cs) 2005-12-14
SI0941117T1 (en) 2002-12-31
GB9623233D0 (en) 1997-01-08
LU91183I2 (fr) 2005-09-20
EP0941117B1 (de) 2002-08-28
DE69715031D1 (de) 2002-10-02
JP3980652B2 (ja) 2007-09-26
EP1240905A1 (de) 2002-09-18
DE69733285T2 (de) 2006-01-12
PT941117E (pt) 2002-12-31
ATE222773T1 (de) 2002-09-15
SI1240905T1 (en) 2005-10-31
PL333127A1 (en) 1999-11-22
CZ164099A3 (cs) 1999-10-13
AU5319698A (en) 1998-05-29
ES2182131T3 (es) 2003-03-01
DE69715031T2 (de) 2003-05-08
NO320186B1 (no) 2005-11-07
DK1240905T3 (da) 2005-07-18
CA2271008C (en) 2008-07-22
EP1240905B3 (de) 2009-08-26
BRPI9712917B8 (pt) 2021-05-25
NO2006005I2 (no) 2010-04-12
ES2240647T7 (es) 2010-03-31
IL129530A0 (en) 2000-02-29
TW471971B (en) 2002-01-11
DE122005000046I1 (de) 2005-12-29
DE69733285D1 (de) 2005-06-16
HK1022638A1 (en) 2000-08-18
NO992156D0 (no) 1999-05-04
HK1050473A1 (en) 2003-06-27
BR9712917A (pt) 1999-12-07
AU710475B2 (en) 1999-09-23
HK1050473B (en) 2006-03-03
HU224126B1 (hu) 2005-05-30
ZA979984B (en) 1998-07-23
IL129530A (en) 2005-11-20
SA98181128B1 (ar) 2006-03-25
TR199900979T2 (xx) 1999-07-21
CY2407B1 (en) 2004-09-10
EP1240905B1 (de) 2005-05-11

Similar Documents

Publication Publication Date Title
ATE295178T1 (de) Azellulärer pertussis-impfstoff, der ein diphtheriae- und tetanus-toxoid enthält
FI953529L (fi) Rokotteita, jotka sisältävät gangliosidi-KLH-konjugaattia ja QS-21-ainetta
BR9711853A (pt) Vacinas
NO891513L (no) Fremgangsmaate og innretning for opphenting av en broennverktoey-/foeringsrammeanordning.
DE69511635D1 (de) Eine Walze
EP0474646A4 (en) Bordetella vaccines
BR9204365A (pt) Saco e metodo para fabricar um saco
HU912864D0 (en) Haemophylus paragallinarum vaccine
GB9017370D0 (en) Tuberculosis vaccine
GB9023660D0 (en) Building identification and other inventions
FI893512L (fi) Bordetella pertussis-vaccin.
GB9611673D0 (en) Meningococcal vaccine
GB9125141D0 (en) A glazing packer
EP0572670A4 (de) Polycaprolactonstapelfase und herstellung.
EP0918725A4 (de) Eine litze
GB9004326D0 (en) Impact nail extractor
EP0912193A4 (de) Impfstoff zur verhütung von streptokokken endocarditis
IE892369L (en) Bordetella pertussis vaccine
IL144200A0 (en) A polynucleotide tuberculosis vaccine
IL89798A0 (en) Key identification aid
FI880644A7 (fi) Menetelmä katteiden ja peitteiden paikallaan pitämiseksi.
IT9058805V0 (it) Chiodo a doppia testa.
AU111251S (en) A rebated brick
IT8912539A0 (it) Tassello ad espansione a rapida messa in opera
GB9314520D0 (en) Vaccines